

Product Name: Napabucasin Revision Date: 01/10/2021

0

# **Product Data Sheet**

# Napabucasin

Cat. No.:	B6029
CAS No.:	8 <mark>3280-</mark> 65-3
Formula:	C14H8O4
M.Wt:	240.21
Synonyms:	
Target:	
Pathway:	
Storage:	Store at -20°C
	810

## Solvent & Solubility

	insoluble in H2O; ins	insoluble in H2O; insoluble in EtOH; $\geq$ 8.7 mg/mL in DMSO			
Preparing In Vitro Stock Solutions		Mass Solvent Concentration	1mg	5mg	10mg
	SICK Solutions	1 mM	4.1630 mL	20.8151 mL	41.6302 mL
	<u>al9</u>	5 mM	0.8326 mL	4.1630 mL	8.3260 mL
	PERMI	10 mM	0.4163 mL	2.0815 mL	4.1630 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary

STAT3 inhibitor

#### IC<sub>50</sub> & Target

In Vitro

Cell Viability Assay	
Cell Line:	PCa cell lines (22RV1and PC-3)
Preparation method:	Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	1 μmol/L, 48, 72, 96, and 120 h

1 | www.apexbt.com

	Applications:	In PCa cell lines PC-3 and 22RV1, Napabucasin (1 $\mu M$ ) inhibited cell		
		proliferation, cell motility, cell survival, colony formation ability and induced cell		
		apoptosis. Napabucasin increased the sensitivity of PCa cells to Docetaxel.		
		Napabucasin treatment decreased the stemness-high cancer cells in PC-3 and		
		22RV1 cells. Napabucasin obviously inhibited both the SP cells from 22RV1		
	<b>al0</b>	cells and CD133+/CD44+ cells from PC-3 cells as well as spheres from PC-3		
	OEL	and 22RV1 cells. In PC-3 stemness-high cancer cells, Napabucasin		
	ally Provent	significantly decreased mRNA expression of Nanog, Klf4, survivin, and		
		β-catenin.		
	Animal experiment			
In Vivo	Animal models:	Immunodeficient nude mouse bearing PC-3 cells or 22RV1 cells		
	Dosage form:	Intraperitoneal injection, 40 mg/kg, every 3 days		
	Applications:	Napabucasin significantly suppressed the tumor growth on prostate cancer		
		(PCa) mouse xenograft models. Treatment with napabucasin resulted in		
	810	inhibition of spherogenesis with numbers of spheres significantly decreased.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
	and the second	slightly differ with the theoretical value. This is caused by an experimental		
		system error and it is normal.		

### **Product Citations**

See more customer validations on www.apexbt.com.



[1]. Zhang Y, Jin Z, Zhou H, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin[J]. Cancer medicine, 2016, 5(6): 1251-1258.

APE

APEABIC

### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

2 | www.apexbt.com













